Brief: Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months
03/04/2025 13:12
April 3 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROA AKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHS Source text: ID:nGNX4P6T4q Further company coverage: AKBA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule